According to filings with the U.S. Securities and Exchange Commission, Alucent Biomedical is raising $11,200,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Myles Greenberg played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Alucent Biomedical
Alucent Medical, Inc. is a privately-held biotechnology company, based in Salt Lake City, UT, developing a novel drug-device combination therapy, Natural Vascular Scaffolding (NVS) for patients with peripheral vascular disease. Alucent Biomedical is a privately held biomedical company focused on a vision to transform the way vascular disease is treated. We develop and deploy advanced technologies to harness the body’s own natural physiologic processes and structures to achieve sustained vessel patency. Alucent’s Natural Vascular Scaffolding (NVS) is a breakthrough technology developed to address the unmet needs of patients with difficult-to-treat vascular diseases, including (but not limited to): Peripheral Artery Disease (PAD) Arteriovenous Fistula (AVF) maturation for dialysis This first-of-its kind technology uses photoactivated protein linking to potentially restore vessels and provide durable patency without the use of stents or other implants. Alucent Biomedical was founded by the Avera Research Institute of Avera Health and became a standalone company is 2017.

To learn more about Alucent Biomedical, visit http://alucentmedical.com/

Contact:
Myles Greenberg, President and Chief Executive Officer
385-722-2300
https://www.linkedin.com/in/mylesgreenberg/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.